Targeted NGS panels in oncology: international standards and domestic solutions towards personalised medicine



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The success of personalized cancer treatment relies on precise diagnostic instruments that can delineate the molecular profile of tumors, thereby enabling the optimization of individualized treatment strategies. Multigene next-generation sequencing (NGS) panels offer a powerful approach for the simultaneous detection of diverse genomic alterations, including single-nucleotide variants, insertions and deletions, copy number changes, and gene fusions, essential for selection of targeted therapies and immunotherapies, and assessing disease prognosis. This review provides a comprehensive perspective of the evolution of precision oncology in the 21st century, with a focus on the transformative role of NGS-based diagnostics in molecular oncology. We examine the technical capabilities and clinical advantages of multigene NGS panels, compare the analytical performance of hybridization- and amplification-based enrichment methods, and discuss their applications in routine oncology practice. Significant focus is directed towards the existing status of NGS diagnostics both within the Russian Federation and worldwide, specifically addressing crucial difficulties that impede the broad integration of multigene NGS panels in oncology clinics throughout Russia.

Full Text

Restricted Access

About the authors

Tatiana S. Gerashchenko

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

Email: t_gerashchenko@oncology.tomsk.ru
ORCID iD: 0000-0002-7283-0092
SPIN-code: 7900-9700
Scopus Author ID: 55948412900
ResearcherId: A-7011-2014
https://www.tnimc.ru/kontakty/personalii/nii-onkologii/gerashchenko-tatyana-sergeevna/

PhD, MD, Senior Researcher at the Laboratory of Cancer Progression Biology

Russian Federation, 5, Kooperativny Street, 634050, Tomsk, Russian Federation.

Polina A. Gervas

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

Email: pgervas@yandex.ru
ORCID iD: 0000-0003-0051-8814
SPIN-code: 2934-7970
Scopus Author ID: 13613767400
ResearcherId: C-5846-2012
https://www.tnimc.ru/kontakty/personalii/nii-onkologii/gervas-polina-anatolevna/

PhD, MD, Senior Researcher at the Laboratory of Molecular Oncology and Immunology

Russian Federation, 5, Kooperativny Street, 634050, Tomsk, Russian Federation.

Arina A. Ibragimova

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

Email: arina.budnitskaya@gmail.com
ORCID iD: 0009-0003-1728-0723
SPIN-code: 3726-8132
ResearcherId: NPJ-0555-2025
https://www.tnimc.ru/kontakty/personalii/nii-onkologii/ibragimova-arina-aleksandrovna/

Junior Researcher at the Laboratory of Cancer Progression Biology

Russian Federation, 5, Kooperativny Street, 634050, Tomsk, Russian Federation.

Andrey S. Zuev

Research Institute of Medical Genetics, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, Russian Federation

Email: Andrew.zuev@medgenetics.ru
ORCID iD: 0000-0001-9474-9335
SPIN-code: 3235-1754
Scopus Author ID: 58187773100
ResearcherId: HIZ-9853-2022
https://www.tnimc.ru/kontakty/personalii/nii-meditsinskoy-genetiki/zuev-andrey-sergeevich/

Junior Researcher at the Laboratory of Instrumental Genomics

Russian Federation, 10, Ushayki River Embankment, 634050, Tomsk, Russian Federation

Maria S. Tretyakova

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

Email: trremar@mail.ru
ORCID iD: 0000-0002-5040-931X
SPIN-code: 5207-8330
Scopus Author ID: 57193234199
ResearcherId: AAX-5003-2020
https://www.tnimc.ru/kontakty/personalii/nii-onkologii/tretyakova-mariya-sergeevna/?theme-scheme=Y

Ph.D. in Biology, Junior Researcher at the Laboratory of Cancer Progression Biology

Russian Federation, 5, Kooperativny Street, 634050, Tomsk, Russian Federation.

Ustinia A. Bokova

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

Email: pushkay@yandex.ru
ORCID iD: 0000-0003-2179-5685
SPIN-code: 3546-0527
Scopus Author ID: 57226147765
ResearcherId: AAX-9705-2021
https://www.tnimc.ru/kontakty/personalii/nii-onkologii/bokova-ustinya-anatolevna/

Ph.D. in Biology, Researcher at the Laboratory of Cancer Progression Biology

Russian Federation, 5, Kooperativny Street, 634050, Tomsk, Russian Federation

Rostislav S. Vorobiev

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

Author for correspondence.
Email: tsu@vorobev.su
ORCID iD: 0000-0002-5705-8479
SPIN-code: 3441-8818
Scopus Author ID: 57204941220
ResearcherId: AAA-4397-2022
https://www.tnimc.ru/kontakty/personalii/nii-onkologii/vorobev-rostislav-sergeevich/

Junior Researcher at the Laboratory of Cancer Progression Biology

Russian Federation, 5, Kooperativny Street, 634050, Tomsk, Russian Federation

Evgeny V. Denisov

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia

Email: d_evgeniy@oncology.tomsk.ru
ORCID iD: 0000-0003-2923-9755
SPIN-code: 9498-5797
Scopus Author ID: 26653961800
ResearcherId: C-8662-2012
https://www.tnimc.ru/kontakty/personalii/nii-onkologii/denisov-evgeniy-vladimirovich/

Doctor of Biology, Head of the Laboratory of Laboratory of Cancer Progression Biology

Russian Federation, 5, Kooperativny Street, 634050, Tomsk, Russian Federation.

References

  1. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363(4):301 –304. doi: 10.1056/NEJMp1006304
  2. Gerashchenko TS, Denisov EV, Litviakov NV, et al. Intratumor heterogeneity: nature and biological significance. Biochemistry (Mosc). 2013;78(11):1201–1215. doi: 10.1134/s0006297913110011 EDN: SLELNR
  3. Zhong Y, Xu F, Wu J, et al. Application of Next Generation Sequencing in Laboratory Medicine. Ann Lab Med. 2021;41(1):25–43. doi: 10.3343/alm.2021.41.1.25 EDN: YPSTFZ
  4. Galeș LN, Păun MA, Butnariu I, et al. Next-Generation Sequencing in Oncology-A Guiding Compass for Targeted Therapy and Emerging Applications. Int J Mol Sci. 2025;26(7). doi: 10.3390/ijms26073123 EDN: OFJHLE
  5. Batra U, Nathany S. Biomarker testing in lung cancer: from bench to bedside. Oncol Rev. 2024;18:1445826. doi: 10.3389/or.2024.1445826 EDN: VCJQBE
  6. Froyen G, Geerdens E, Berden S, et al. Diagnostic Validation of a Comprehensive Targeted Panel for Broad Mutational and Biomarker Analysis in Solid Tumors. Cancers (Basel). 2022;14(10). doi: 10.3390/cancers14102457 EDN: DGUKQI
  7. Kroeze LI, de Voer RM, Kamping EJ, et al. Evaluation of a Hybrid Capture-Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes. J Mol Diagn. 2020;22(6):757–769. doi: 10.1016/j.jmoldx.2020.02.009 EDN: URQACV
  8. Anand U, Dey A, Chandel AKS, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2023;10(4):1367–1401. doi: 10.1016/j.gendis.2022.02.007 EDN: UIEUZJ
  9. Scott EC, Baines AC, Gong Y, et al. Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat Rev Drug Discov. 2023;22(8):625–640. doi: 10.1038/s41573-023-00723-4 EDN: SRKWUM
  10. Zalli D, Mai Z, Ferati E, Ramaj A, Bregu R, Pranjol MZI. Advancing Precision Medicine. In: Rezaei N, editor. Cancer Personalized Treatment. Handbook of Cancer and Immunology. Springer; 2025. P:27–57.
  11. Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJM. The future of precision oncology. Int J Mol Sci. 2023;24(16):12613. doi: 10.3390/ijms241612613 EDN: BLQDSC
  12. Pugh TJ, Bell JL, Bruce JP, et al. AACR Project GENIE: 100,000 Cases and Beyond. Cancer Discov. 2022;12(9):2044–2057. doi: 10.1158/2159-8290.cd-21-1547 EDN: DRHJBJ
  13. Imyanitov E, Sokolenko A. Molecular diagnostics in clinical oncology: an overview. Explor Med. 2025;6:1001346. doi: 10.37349/emed.2025.1001346 EDN: XYMVKH
  14. Zhou Z, Li M. Targeted therapies for cancer. BMC Medicine. 2022;20(1):90. doi: 10.1186/s12916-022-02287-3
  15. Mateo J, Steuten L, Aftimos P, et al. Delivering precision oncology to patients with cancer. Nat Med. 2022;28(4):658–665. doi: 10.1038/s41591-022-01717-2 EDN: RTSYQW
  16. Tsimberidou AM, Kahle M, Vo HH, et al. Molecular tumour boards — current and future considerations for precision oncology. Nat Rev Clin Oncol. 2023;20(12):843–863. doi: 10.1038/s41571-023-00824-4
  17. Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bièche I, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024;35(7):588–606. doi: 10.1016/j.annonc.2024.04.005 EDN: BEMSHO
  18. Lyander A, Gellerbring A, Hägglund M, Elhami K, Wirta V. NGS method for parallel processing of high quality, damaged or fragmented input material using target enrichment. PLoS One. 2024;19(5):e0304411. doi: 10.1371/journal.pone.0304411 EDN: IVBSFL
  19. Vashisht V, Vashisht A, Mondal AK, Woodall J, Kolhe R. From genomic exploration to personalized treatment: next-generation sequencing in oncology. Curr Issues Mol Biol. 2024;46(11):12527–12549. doi: 10.3390/cimb46110744 EDN: IJWJYS
  20. Kozarewa I, Armisen J, Gardner AF, et al. Overview of Target Enrichment Strategies. Curr Protoc Mol Biol. 2015;112:7.21.1–7.21.23. doi: 10.1002/0471142727.mb0721s112
  21. Singh RR. Target Enrichment Approaches for Next-Generation Sequencing Applications in Oncology. Diagnostics. 2022;12(7):1539. doi: 10.3390/diagnostics12071539 EDN: UZSNPO
  22. Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn. 2015;17(3):251–264. doi: 10.1016/j.jmoldx.2014.12.006
  23. Schenk D, Song G, Ke Y, Wang Z. Amplification of overlapping DNA amplicons in a single-tube multiplex PCR for targeted next-generation sequencing of BRCA1 and BRCA2. PLoS One. 2017;12(7):e0181062. doi: 10.1371/journal.pone.0181062
  24. Dumur CI., Krishnan R, Almenara JA, et al. Analytical Validation and Clinical Utilization of the Oncomine Comprehensive Assay Plus Panel for Comprehensive Genomic Profiling in Solid Tumors. Journal of Molecular Pathology. 2023;4(2):109–127. doi: 10.3390/jmp4020012 EDN: DGIHBH
  25. Sahoo OS, Aidasani H, Nayek A, et al. Role of next‐generation sequencing in revolutionizing healthcare for cancer management. MedComm – Future Med. 2024;3:e70001. doi: 10.1002/mef2.70001 EDN: QLOYKK
  26. Yao J, Zhai Q. A narrative review of cancer molecular diagnostics: past, present, and future. J Bio-X Res. 2022;5:145–150. doi: 10.1097/JBR.0000000000000136 EDN: MSGVCQ
  27. Doig KD, Love CG, Conway T, et al. Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics. BMC Med Genomics. 2022;15:70. doi: 10.1186/s12920-022-01214-y EDN: OXXKAV
  28. Mirza M, Goerke L, Anderson A, et al. Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review. Value Health. 2024;27(9):1300–1309. doi: 10.1016/j.jval.2024.04.023 EDN: OMERSG
  29. Jørgensen JT. The current landscape of the FDA approved companion diagnostics. Transl Oncol. 2021;14(6):101063. doi: 10.1016/j.tranon.2021.101063 EDN: DPVJVY
  30. Ratner M. First multi-gene NGS diagnostic kit approved. Nat Biotechnol. 2017;35(8):699. doi: 10.1038/nbt0817-699
  31. Shelyakin VA, Linnik SA, Tretyakov DA, et al. Analyses of the effectiveness of molecular genetic testing of patients with cancer on the examples of some subjects of the Russian Federation as the basis for the use of targeted drugs. Bull Natl Res Inst Public Health N.A. Semashko. 2022;4:30–37. doi: 10.25742/NRIPH.2022.04.006 EDN: XVNQGP

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 86496 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ЭЛ № ФС 77 - 80673 от 23.03.2021 г.